Articles tagged with Cancer
A study by Zhejiang University reveals how IL-6 reprograms PD-L1 expression in colorectal cancer stem cells, driving immunosuppressive effects. Dual-target therapy combining PI3K and STAT3 inhibitors shows promise in overcoming immunotherapy resistance.
A new deep learning model, MSI-SEER, achieves high accuracy in predicting microsatellite instability-high tumors and their responsiveness to immunotherapy. The model combines tumor MSI status with stroma-to-tumor ratio for highly accurate ICI response prediction.
A new study by the Germans Trias i Pujol Research Institute expands and optimizes 3D models to investigate colorectal cancer. The results show that different culture conditions affect spheroid morphology and compactness, highlighting the need for standardization.
Researchers explore emerging role of extracellular RNAs in cancer diagnosis, prognosis, and treatment. These natural nanocarriers can reflect tumor behavior in real time and deliver targeted therapies.
Researchers found that automatically mailing a stool-based screening test resulted in the highest screening rates among adults aged 45-49. The study, which included over 20,000 patients, showed that this approach can encourage timely screening and potentially save lives.
Local-stage colorectal cancer incidence among US adults ages 45-49 increased by 50% between 2021 and 2022, with a steep rise in 2019-2022. Screening rates also increased during this period, driven by recommendations to start screening at age 45.
Researchers at University of Alabama at Birmingham identify Gfi1 as a crucial regulator of exhausted CD8+ T cell subsets. Fine-tuning Gfi1 activity may prevent or reverse T cell exhaustion, bolstering immune checkpoint blockade therapy. The study suggests potential for improving cancer treatment and controlling chronic infections.
Researchers at UCLA have successfully created a continuous supply of functional T cells using genetically engineered stem cells. This breakthrough could lead to longer-lasting protection against cancer and potentially treat other diseases such as HIV or autoimmune disorders.
Researchers have developed a novel technology that can simultaneously silence two notoriously difficult-to-target cancer-related genes, KRAS and MYC. This innovation has the potential to treat cancers that have been challenging to treat, with significant implications for patients.
Researchers have identified a protein called eIF2A that plays a crucial role in guiding melanoma cancer cells as they spread throughout the body. Targeting this protein could be a new approach to impede metastasis and improve healthcare outcomes for patients with melanoma.
Hollings researchers use natural language processing to identify primary cancer types in medical notes, improving treatment accuracy and personalized care. The AI model achieves high accuracy rates, outperforming standard medical codes in identifying primary cancer diagnoses.
Researchers from Kumamoto University identified a genetic 'silencer' element that keeps the human T-cell leukemia virus type 1 (HTLV-1) in a dormant state, evading immune detection. This discovery offers hope for new therapeutic approaches to treat HTLV-1 and potentially even HIV.
Research suggests that consuming high levels of sucralose can make cancer treatment less effective by disrupting the gut microbiome and altering T cell function. However, adding arginine or citrulline supplements to the diet may restore immunotherapy effectiveness in patients with melanoma and non-small cell lung cancer.
A study of ovarian tumor immune landscapes reveals four distinct immunologic subtypes, with those with T cells surviving longer and having better outcomes. The researchers also found that myeloid cells play a key role in reestablishing the immune landscape upon recurrence.
A study using anonymized patient records from UC health centers found over 600 correlations between endometriosis and other conditions, including infertility, autoimmune disease, and certain cancers. The research supports the growing understanding of endometriosis as a multi-system disorder.
Gemini achieved highest accuracy, followed by Claude-3-opus and GPT, with accuracy varying significantly across single-image tasks and continuous slices. Simplified prompts improved diagnostic performance, but Gemini and GPT struggled with normal image recognition.
A global analysis of CAR-T cell therapy found a significantly increased risk of developing secondary cancers, particularly T-cell lymphoma and myelodysplastic syndromes. The median onset of these cancers occurred much earlier in CAR-T recipients compared to those not receiving the treatment.
The CPADS web tool integrates data from GEO, TCGA, and GDSC databases to analyze gene expression changes, correlations between genes or drugs, and pathway enrichment in cancer samples. L1CAM was identified as a potential drug resistance target in non-small cell lung cancer through CPADS analysis.
A new study uses GenAI models to extract pathological features for lung adenocarcinoma grading and prognosis, achieving striking accuracy and consistency. The research team discovered 11 key histological features and 4 clinical variables that provide a comprehensive risk assessment for patients.
Researchers discovered that a type of HPV commonly found on the skin can directly cause a form of skin cancer called cutaneous squamous cell carcinoma when immune cells malfunction. The study's findings suggest that other people with defective T-cell responses may also be susceptible to cancer caused directly by beta-HPV.
Researchers have developed a predictive tool that can identify patients with nasopharyngeal carcinoma most likely to benefit from radiotherapy. The model uses transcriptomic data and machine learning to evaluate 113 algorithm combinations, identifying an 18-gene signature associated with radiosensitivity.
A global study found that cancer immunotherapies carry a hidden risk: cholestasis, a serious liver condition. Researchers urge aggressive monitoring of liver function, particularly in younger adults and women.
Researchers discovered that cancer cells have a defensive mechanism to repair DNA damage and survive physical stress by activating mitochondria to pump in extra ATP. This finding could lead to new therapeutic approaches by targeting the mechanism's underlying scaffold.
This book presents cutting-edge approaches to combat cancer, including exosomal delivery systems, CRISPR/Cas9 gene editing, and immunotoxin therapy. Natural compounds are also examined for their anticancer potential.
The THER web tool analyzes hypoxia-associated transcriptomic data without programming skills, presenting results via volcano plots, heatmaps, and tables. Experimental validation confirms THER's reliability, revealing broad impacts of hypoxia on drug efficacy across tumor types.
Recent AI-based models, such as Asian Prostate Cancer Artificial Intelligence and Galen Prostate, optimize screening and reduce unnecessary biopsies. These models use multimodal clinical parameters and convolutional neural networks to detect prostate cancer and identify aggressiveness of cancer cells.
Research reveals obesity's role in cancer development through mechanisms like chronic inflammation, hormonal disorders, and microbial dysbiosis. Lifestyle changes and targeted treatments hold potential in preventing obesity-related cancers.
Researchers at McMaster University have developed a promising new treatment for liver cancer by targeting metabolism in tumours. The discovery, published in Nature, shows that inhibiting an enzyme called ATP citrate lyase can enable the immune system to kill liver cancer cells, particularly through B cell-mediated responses.
Cancer-associated fibroblasts (CAFs) exhibit paradoxical effects on immunotherapy, sometimes hindering and other times helping to control tumors. Research identifies specific CAF subtypes that enhance or suppress immune cells, offering promising targets for therapies.
Researchers map the path from liver fibrosis to cancer, revealing how scarred liver tissue becomes a breeding ground for tumor growth. Key findings include the role of hepatic stellate cells and dysregulated signaling pathways in remodeling the liver into a pro-tumor environment.
A decade-long study reveals that the source of dietary fat, not adiposity itself, is the primary factor influencing tumor growth in obese mice. High-fat diets derived from animal fats compromise anti-tumor immunity and accelerate tumor growth, while plant-based fats have a neutral effect.
Researchers found that common respiratory infections like COVID-19 and influenza can awaken dormant breast cancer cells in the lungs, leading to a massive expansion of metastatic cells. The study suggests that individuals with a history of cancer may benefit from taking precautions against respiratory viruses.
Researchers analyzed data from over 10,000 solid tumor samples and found that more than 90 percent contained genetic changes that could guide treatment. The study identified biomarkers associated with approved therapies and rare mutations missed by simpler tests.
A new study found that immunotherapy may change the bone marrow environment where cancer cells live, potentially helping the immune system respond more effectively. Researchers tracked how the immune system interacts with cancer cells after treatment and noticed changes in cellular neighborhoods and cell communication.
The American College of Chest Physicians has released a clinical guideline on the management of patients with early-stage non-small cell lung cancer. The guideline provides evidence-based recommendations for primary treatment and outlines three flowchart graphs outlining the recommended course of treatment based on patient risk. These ...
Researchers at Chiba University have developed novel microfluidic devices that incorporate microcones to detect and characterize circulating tumor cells in blood. The devices demonstrated highly selective capture of human breast and lung cancer cells, with high efficiency even at high flow rates.
A UCLA-led study found that while blood-based tests offer a convenient option for screening, only 49% of patients completed a follow-up colonoscopy within six months. The study's findings highlight the need for improved follow-up care to detect and treat colorectal cancer effectively.
Weill Cornell Medicine researchers found that PD-1 plays a critical role in forming long-term immune defenders in the skin. Blocking PD-1 too early can disrupt this process, leading to side effects. The study challenges current understanding of PD-1 and may impact cancer treatments.
Researchers will evaluate technology as a clinical tool for personalized cancer therapy, with potential to test various treatments on patient biopsies. The collaboration aims to obtain CAP/CLIA certification and conduct clinical studies to validate the utility of organoid-based assays.
Researchers have pinpointed six pivotal signaling pathways driving osteosarcoma progression, offering a roadmap for developing precision therapies. Targeting these pathways simultaneously may curb both primary growth and metastasis in osteosarcoma patients.
The 250,000-square-foot facility provides greater availability to high-quality integrated care, addressing the region's increasing demand for innovative diagnostic and treatment services. The pavilion brings together a broad range of nationally ranked clinical programs, including cancer clinics, neurology, and surgery.
Researchers at UC San Diego School of Medicine have developed a novel approach to enhance the effectiveness of immunotherapy treatments for head and neck squamous cell carcinomas (HNSCC). Delivering radiation therapy that preserves tumor-draining lymph nodes followed by immunotherapy resulted in a complete and durable tumor response in...
A single bout of exercise increases myokine levels, reducing cancer growth by 20-30%. Regular exercise helps reduce inflammation and improve body composition, leading to a lower risk of recurrence and mortality.
A study published in Cancer Biology & Medicine found that combining mitochondrial transplantation with cisplatin enhances immune cell infiltration, reverses tumor metabolism, and improves the effectiveness of chemotherapy. This innovative approach shows potential to reshape how lung tumors are treated.
Three in five liver cancer cases can be prevented by reducing viral hepatitis, alcohol consumption, and metabolic dysfunction-associated steatotic liver disease. The Lancet Commission estimates that if countries can reduce liver cancer incidence by 2-5% annually by 2050, it could prevent 9-17 million new cases and save 8-15 million lives.
A new silicone patch with star-shaped microneedles, called the ExoPatch, distinguishes melanoma from healthy skin in mice, capturing cancer biomarkers from exosomes. The test shows promise for early detection of the most aggressive form of skin cancer without a biopsy or blood draw.
Researchers have discovered a promising new approach to suppress the growth of aggressive cancers by targeting minor splicing, a specialized molecular process. By blocking minor splicing, cancer cells accumulate DNA damage and trigger cell death, while healthy cells remain largely unaffected.
Scientists have found that nucleosomes act as gatekeepers for p53's molecular partners, controlling its access to the genetic code. This discovery reveals a new layer of regulation over p53's activity and opens possibilities for developing cancer therapies that restore or control p53 function.
A team of scientists from the University of Konstanz has identified the PPM1F enzyme as essential for cell migration in both embryonic development and tumor cell invasion. The study found that increased levels of PPM1F enhance the invasive potential of cancer cells, while its absence impairs cell adhesion and migration.
Colorectal cancer claims more lives in Black communities than any other racial group, with incidence and mortality rates about 20% and 30% higher respectively. A new review by UCLA researchers highlights the need for equal access to screening, diagnosis, and treatment to eliminate these disparities.
A new study identified seven immune-related genes downregulated in hepatocellular carcinoma and intrahepatic cholangiocarcinoma, which are associated with immune surveillance and complement pathways. The findings also revealed macrophage migration inhibitory factor signaling as a critical communication channel in ICC.
Researchers at Fralin Biomedical Research Institute have identified a potential target for experimental drugs that block PRMT5, a naturally occurring enzyme some tumors rely on for survival. The study found a new drug combination that works against certain hard-to-treat cancers.
Researchers at Sanford Burnham Prebys found that blocking macropinocytosis reshapes the tumor microenvironment, allowing more access to immune cells. This change made immunotherapy and chemotherapy more effective in treating PDAC tumors in mice.
A new case report describes the use of extracorporeal blood filtration to treat stage IV poorly differentiated pancreatic adenocarcinoma. The patient experienced clinical improvement, reduced pain, and no signs of new tumor growth over 12 months of follow-up.
The Josep Carreras Leukaemia Research Institute is launching a joint research programme on childhood leukaemia, aiming to develop common strategies and improve treatments for the disease. Paediatric leukaemia remains a significant challenge due to its low incidence and high mortality rate.
Diana Hargreaves will receive $1 million to advance her project on improving immunotherapy in patients with pancreatic cancer. Her previous work identified better drug targets for cancers with SWI/SNF mutations, leading to breakthroughs in treating difficult-to-treat cancers.
Researchers found that oxidative stress actually suppressed cancer development in rats with BRCA2 gene mutations, contrary to prior expectations. This discovery suggests that avoiding radiation exposure may not be the best method for people with BRCA2 pathological variants.
A team from The Hebrew University of Jerusalem has developed innovative druglike molecules capable of degrading HuR, a key RNA-binding protein that stabilizes oncogenes and fuels cancer progression. These molecular degraders improve anticancer properties by up to 3-4 orders of magnitude compared to traditional HuR-binding molecules.
A study published in Nature found that autoantibodies can tilt the odds dramatically toward shrinking tumors and enhance the effectiveness of immunotherapy. Certain autoantibodies linked to better clinical outcomes could reveal cancer's weak spots and point to new targets for treatment.
Researchers discovered a compound, EPS3.9, produced by deep-sea bacteria that triggers pyroptosis to inhibit tumor growth and exhibit potent anti-cancer effects. The study highlights the importance of exploring marine microbial resources for developing new drugs.